echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > To further test the effect of Aduhelm, Bojian plans to start confirmatory clinical trials

    To further test the effect of Aduhelm, Bojian plans to start confirmatory clinical trials

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 16, 2021, Biogen and Eisai announced that they are expected to start a large confirmatory clinical trial in May next year to further evaluate Alzheimer's disease (AD) monoclonal antibodies Efficacy of therapy Aduhelm (aducanumab)


    Aducanumab is a monoclonal antibody that directly targets amyloid beta (Aβ)


    Aduhelm's approval in June was based on the accelerated approval channel


    Bojian’s press release pointed out that the trial will recruit more than 1,300 early-stage AD patients.


    Reference materials:

    [1] Biogen Preps for Post-Approval Testing of Controversial Alzheimer's Drug.


    [2] All Approvals and Tentative Approvals December 2021.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.